Tech News, Tech & Coding · Free Online Tools

IT Question Answer
Tools
Back to Biotech & Health
FDA accepts uniQure's Huntington's disease gene therapy application for priority review

FDA accepts uniQure's Huntington's disease gene therapy application for priority review

Biotech & HealthBy Muhammad FareedBioPharm International; MarketBeat Q3 call coverage; Huntington's Disease News
uniqureamt-130huntington's diseasegene therapyfda

What the FDA decided

The US Food and Drug Administration accepted uniQure's Biologics License Application (BLA) for AMT-130 (ifezuntirgene inilparvovec), a gene therapy for Huntington's disease, and granted it priority review under the accelerated approval pathway. The announcement was dated November 2, 2026. The target action date under the Prescription Drug User Fee Act is May 1, 2027. The FDA also indicated it is tentatively planning to discuss the application at an advisory committee meeting, with the date not yet set.

What the application is based on

  • 36-month data from phase 1/2 studies.
  • A comparison with a propensity score-matched external control drawn from the Enroll-HD natural history database, instead of a randomized placebo group.

The FDA had earlier questioned whether this kind of data could serve as primary evidence. After a Type B meeting in June 2026, uniQure and the FDA reached alignment that the existing 36-month clinical data could support a BLA submission under the accelerated approval pathway.

What priority review means

Priority review aims to shorten the review from a standard ten months to six months. It is a speed designation for the review process and not a prediction about approval. Acceptance of the application does not guarantee approval.

Confirmatory study

uniQure expects patient screening for a confirmatory study to begin before the end of 2026. Accelerated approval usually requires such a study to verify benefit.

Why it matters

Huntington's disease is an inherited neurodegenerative disorder with no approved therapy that slows its progression. A gene therapy that changes the course of the disease would be a major advance. The use of an external control rather than a placebo group makes the review closely watched, because it tests how far regulators will rely on natural history comparisons for rare diseases.

What to watch

  • The date of the advisory committee and how the panel discusses the external control.
  • Safety and durability data as follow-up continues.
  • The FDA's decision around the May 1, 2027 target date.

The coverage reviewed came from secondary outlets and the company's quarterly call summary, not the official press release, so confirm details with uniQure and the FDA. For another approval this month, see our report on dostarlimab for rectal cancer.

Advertisement